1. Home
  2. BEAM vs REZI Comparison

BEAM vs REZI Comparison

Compare BEAM & REZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.87

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Resideo Technologies Inc.

REZI

Resideo Technologies Inc.

N/A

Current Price

$18.63

Market Cap

2.7B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
REZI
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Wholesale Distributors
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
BEAM
REZI
Price
$26.87
$18.63
Analyst Decision
Strong Buy
Buy
Analyst Count
15
6
Target Price
★ $49.38
$29.83
AVG Volume (30 Days)
★ 1.8M
1.7M
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
N/A
EPS
N/A
★ 0.68
Revenue
$24,000.00
★ $7,472,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14.48
N/A
P/E Ratio
★ N/A
$27.65
Revenue Growth
★ 33.33
10.52
52 Week Low
$20.23
$15.90
52 Week High
$38.26
$43.04

Technical Indicators

Market Signals
Indicator
BEAM
REZI
Relative Strength Index (RSI) 55.77 57.71
Support Level $25.29 $15.90
Resistance Level $28.87 $19.00
Average True Range (ATR) 1.47 0.61
MACD 0.47 0.34
Stochastic Oscillator 55.38 90.60

Price Performance

Historical Comparison
BEAM
REZI

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About REZI Resideo Technologies Inc.

Resideo Technologies Inc manufactures, develops, and distributes sensing and control products and solutions for residential and commercial markets. Its product portfolio includes heating, ventilation, and air conditioning (HVAC) controls, smoke and carbon monoxide detection products, fire suppression products, and security products. Its products and solutions are used in residential and commercial buildings across various countries.

Share on Social Networks: